<?xml version='1.0' encoding='utf-8'?>
<document id="11552225"><sentence text="Pharmacokinetic profiles of doxorubicin in combination with taxanes."><entity charOffset="28-39" id="DDI-PubMed.11552225.s1.e0" text="doxorubicin" /><entity charOffset="60-67" id="DDI-PubMed.11552225.s1.e1" text="taxanes" /><pair ddi="false" e1="DDI-PubMed.11552225.s1.e0" e2="DDI-PubMed.11552225.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11552225.s1.e0" e2="DDI-PubMed.11552225.s1.e1" /></sentence><sentence text="Paclitaxel and docetaxel each possess unique chemical and pharmacologic characteristics that account for significant differences in their potencies, toxicologic and pharmacokinetic profiles, and propensity for drug-drug interactions"><entity charOffset="0-10" id="DDI-PubMed.11552225.s2.e0" text="Paclitaxel" /><entity charOffset="15-24" id="DDI-PubMed.11552225.s2.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.11552225.s2.e0" e2="DDI-PubMed.11552225.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11552225.s2.e0" e2="DDI-PubMed.11552225.s2.e1" /></sentence><sentence text=" Results from phase I/II trials of paclitaxel in combination with doxorubicin showed excellent antitumor activity"><entity charOffset="35-45" id="DDI-PubMed.11552225.s3.e0" text="paclitaxel" /><entity charOffset="66-77" id="DDI-PubMed.11552225.s3.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.11552225.s3.e0" e2="DDI-PubMed.11552225.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11552225.s3.e0" e2="DDI-PubMed.11552225.s3.e1" /></sentence><sentence text=" However, the high incidence of congestive heart failure warranted further investigation" /><sentence text=" A sophisticated pharmacokinetic study showed that paclitaxel enhances the nonlinearity of doxorubicin pharmacokinetics and significantly decreases the systemic clearance of both doxorubicin and doxorubicinol"><entity charOffset="51-61" id="DDI-PubMed.11552225.s5.e0" text="paclitaxel" /><entity charOffset="91-102" id="DDI-PubMed.11552225.s5.e1" text="doxorubicin" /><entity charOffset="179-190" id="DDI-PubMed.11552225.s5.e2" text="doxorubicin" /><entity charOffset="195-208" id="DDI-PubMed.11552225.s5.e3" text="doxorubicinol" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e0" e2="DDI-PubMed.11552225.s5.e0" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e0" e2="DDI-PubMed.11552225.s5.e1" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e0" e2="DDI-PubMed.11552225.s5.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e0" e2="DDI-PubMed.11552225.s5.e3" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e1" e2="DDI-PubMed.11552225.s5.e1" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e1" e2="DDI-PubMed.11552225.s5.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e1" e2="DDI-PubMed.11552225.s5.e3" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e2" e2="DDI-PubMed.11552225.s5.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s5.e2" e2="DDI-PubMed.11552225.s5.e3" /></sentence><sentence text=" The paclitaxel/doxorubicin interaction was found to be paclitaxel-dose dependent, doxorubicin concentration-dependant, and may be the result of competition for elimination mechanisms, possibly competition for hepatic and biliary transporter proteins such as p-glycoprotein, as a result of the formulation vehicle polyethoxylated castor oil (cremophor EL)"><entity charOffset="5-15" id="DDI-PubMed.11552225.s6.e0" text="paclitaxel" /><entity charOffset="16-27" id="DDI-PubMed.11552225.s6.e1" text="doxorubicin" /><entity charOffset="56-66" id="DDI-PubMed.11552225.s6.e2" text="paclitaxel" /><entity charOffset="83-94" id="DDI-PubMed.11552225.s6.e3" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e0" e2="DDI-PubMed.11552225.s6.e0" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e0" e2="DDI-PubMed.11552225.s6.e1" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e0" e2="DDI-PubMed.11552225.s6.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e0" e2="DDI-PubMed.11552225.s6.e3" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e1" e2="DDI-PubMed.11552225.s6.e1" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e1" e2="DDI-PubMed.11552225.s6.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e1" e2="DDI-PubMed.11552225.s6.e3" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e2" e2="DDI-PubMed.11552225.s6.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s6.e2" e2="DDI-PubMed.11552225.s6.e3" /></sentence><sentence text=" Phase I/II trials of the docetaxel/doxorubicin combination also show high antitumor activity, but without an increase in anthracycline-induced congestive heart failure"><entity charOffset="26-35" id="DDI-PubMed.11552225.s7.e0" text="docetaxel" /><entity charOffset="36-47" id="DDI-PubMed.11552225.s7.e1" text="doxorubicin" /><entity charOffset="122-135" id="DDI-PubMed.11552225.s7.e2" text="anthracycline" /><pair ddi="false" e1="DDI-PubMed.11552225.s7.e0" e2="DDI-PubMed.11552225.s7.e0" /><pair ddi="false" e1="DDI-PubMed.11552225.s7.e0" e2="DDI-PubMed.11552225.s7.e1" /><pair ddi="false" e1="DDI-PubMed.11552225.s7.e0" e2="DDI-PubMed.11552225.s7.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s7.e1" e2="DDI-PubMed.11552225.s7.e1" /><pair ddi="false" e1="DDI-PubMed.11552225.s7.e1" e2="DDI-PubMed.11552225.s7.e2" /></sentence><sentence text=" Subsequent pharmacokinetic investigations show minimal alterations in the pharmacokinetic profiles of doxorubicin or docetaxel when used in combination"><entity charOffset="103-114" id="DDI-PubMed.11552225.s8.e0" text="doxorubicin" /><entity charOffset="118-127" id="DDI-PubMed.11552225.s8.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.11552225.s8.e0" e2="DDI-PubMed.11552225.s8.e0" /><pair ddi="false" e1="DDI-PubMed.11552225.s8.e0" e2="DDI-PubMed.11552225.s8.e1" /></sentence><sentence text=" While both paclitaxel and docetaxel may be effectively combined with doxorubicin in the treatment of metastatic breast cancer, the drug-drug interaction between paclitaxel and doxorubicin (but not of docetaxel and doxorubicin) warrants that certain restrictions be followed for safe use"><entity charOffset="12-22" id="DDI-PubMed.11552225.s9.e0" text="paclitaxel" /><entity charOffset="27-36" id="DDI-PubMed.11552225.s9.e1" text="docetaxel" /><entity charOffset="70-81" id="DDI-PubMed.11552225.s9.e2" text="doxorubicin" /><entity charOffset="162-172" id="DDI-PubMed.11552225.s9.e3" text="paclitaxel" /><entity charOffset="177-188" id="DDI-PubMed.11552225.s9.e4" text="doxorubicin" /><entity charOffset="201-210" id="DDI-PubMed.11552225.s9.e5" text="docetaxel" /><entity charOffset="215-226" id="DDI-PubMed.11552225.s9.e6" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e0" e2="DDI-PubMed.11552225.s9.e0" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e0" e2="DDI-PubMed.11552225.s9.e1" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e0" e2="DDI-PubMed.11552225.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e0" e2="DDI-PubMed.11552225.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e0" e2="DDI-PubMed.11552225.s9.e4" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e0" e2="DDI-PubMed.11552225.s9.e5" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e0" e2="DDI-PubMed.11552225.s9.e6" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e1" e2="DDI-PubMed.11552225.s9.e1" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e1" e2="DDI-PubMed.11552225.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e1" e2="DDI-PubMed.11552225.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e1" e2="DDI-PubMed.11552225.s9.e4" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e1" e2="DDI-PubMed.11552225.s9.e5" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e1" e2="DDI-PubMed.11552225.s9.e6" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e2" e2="DDI-PubMed.11552225.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e2" e2="DDI-PubMed.11552225.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e2" e2="DDI-PubMed.11552225.s9.e4" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e2" e2="DDI-PubMed.11552225.s9.e5" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e2" e2="DDI-PubMed.11552225.s9.e6" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e3" e2="DDI-PubMed.11552225.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e3" e2="DDI-PubMed.11552225.s9.e4" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e3" e2="DDI-PubMed.11552225.s9.e5" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e3" e2="DDI-PubMed.11552225.s9.e6" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e4" e2="DDI-PubMed.11552225.s9.e4" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e4" e2="DDI-PubMed.11552225.s9.e5" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e4" e2="DDI-PubMed.11552225.s9.e6" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e5" e2="DDI-PubMed.11552225.s9.e5" /><pair ddi="false" e1="DDI-PubMed.11552225.s9.e5" e2="DDI-PubMed.11552225.s9.e6" /></sentence><sentence text="" /></document>